FDA Warning Letter to Noven Pharmaceuticals
August 19, 2016
FDA has issued a Warning Letter to Noven Pharmaceuticals, Inc. (Miami, FL) pointing to a number of problems with measurement, analysis and testing, as well as insufficient attention to customer complaints and their root causes.
Customer complaints for one product reportedly increased by 50% from 2013 to 2014, inspectors noted, but Noven had failed to determine the root causes of problems. Inspectors trace that to inadequate testing methods.
Noven’s staff members had also failed to validate test methods to detect adhesive transfer, FDA said, which would remove the drug from the product, rendering it unusable.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
